Misti’s acoustic nebuliser mask offers child-friendly, efficient respiratory relief, reducing hospital visits and waiting times.

When a child’s sniffles turn into coughing, then hacking, their condition worsens. It could be minor, or something more. As their discomfort grows, so does their parents’ stress, leading to a visit to the GP for relief and peace of mind.

Globally, 545 million people visit clinics annually with severe respiratory conditions. Among children, respiratory syncytial virus (RSV) is the leading cause, responsible for over 60% of acute respiratory illnesses, and can result in lower respiratory tract infections like pneumonia. RSV hospitalises 3.6 million children each year, with 1 in 5 infants visiting the GP for RSV by age 2.

Children experience an average of 12 viral illnesses annually, leading to missed school days, doctor visits and parents taking time off work. Early respiratory care can reduce this cycle with treatments that are accessible, effective and effortless – and that can be administered at home.

Inhalation therapy offers fast relief for children with viral infections by delivering medication directly to the lungs, aiming to reduce symptoms, prevent complications and shorten illness duration. Current at-home solutions often fall short. Nasal sprays may irritate delicate nasal passages, inhaler outcomes can be inconsistent if not used correctly, snot suckers are uncomfortable and only temporarily effective, and steam vaporisers may fail to maintain safe humidity levels.

Medical-grade nebulisers that aerosolise medication can be especially beneficial for young children, as they are easier to use and provide better medication delivery. Most convert liquid medication into a mist using compressed air, ultrasonic vibrations or mesh to form the correct size of droplet. However, these nebulisers can be noisy and may deliver medication inefficiently, with only 50–75% of loaded medication converted to mist, leading to prolonged treatment times and wasted medication.